EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2018, after the market close, and will host a corporate update conference call and webcast on Monday, August 6, 2018, at 4:30 PM Eastern Time.
Conference Call Details
Monday, August 6th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
Toll Free: 800-263-0877
Conference ID: 1390518
Replays, Available through August 20th:
Replay PIN: 1390518
Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company dedicated to developing therapies for people living with severe central nervous system (CNS) disorders who have limited or no treatment options. Led by a team of experts in rare disease development and CNS conditions, Zogenix is rapidly advancing the clinical investigation and development of ZX008 (fenfluramine hydrochloride) for patients with severe, rare epilepsies, including Dravet and Lennox-Gastaut syndromes.
For more information, visit www.zogenix.com.
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Source: Zogenix, Inc.